NextFin News - Shalby Limited, the Ahmedabad-headquartered healthcare giant synonymous with orthopedic dominance, has officially pivoted toward a multi-specialty future with the inauguration of a full-scale oncology department at Krishna Shalby Hospital today. The launch, which includes advanced radiotherapy facilities, marks a decisive attempt by the Vikram Shah-led group to capture a larger share of India’s high-margin tertiary care market. By integrating medical, radiation, and surgical oncology under one roof in its home turf, Shalby is signaling that its days as a "single-specialty plus" player are over.
The timing of this expansion is no coincidence. According to a recent exchange filing, the new department is equipped with high-end diagnostic and treatment technology designed to provide a "one-stop" solution for cancer patients in and around Ahmedabad. This move follows a similar launch in Surat earlier this month, suggesting a rapid-fire rollout of oncology services across Shalby’s 17-hospital network. For a company that built its reputation on performing over 15% of all joint replacement surgeries in India’s private sector, the shift into oncology represents a necessary evolution to de-risk its revenue streams.
Financially, the pivot is a play for higher Average Revenue Per Occupied Bed (ARPOB). While orthopedics remains a steady cash cow, oncology typically commands higher margins due to the complexity of treatment and the recurring nature of chemotherapy and radiotherapy sessions. During an earnings call in February 2026, Shanay Shah, Shalby’s President, indicated that the company’s growth plan involves squeezing 60% to 70% more productivity out of existing assets through infrastructure upgrades and robotics. The Krishna Shalby expansion is the physical manifestation of that strategy, utilizing existing real estate to house high-value specialties.
The competitive landscape in Ahmedabad is already crowded, with players like Apollo and HCG (Healthcare Global Enterprises) holding significant mindshare in cancer care. Shalby’s entry into this space relies on its massive existing patient base and its brand equity in Gujarat. By offering integrated care—where a patient doesn't have to leave the facility for a PET scan or a radiation cycle—Shalby is betting it can convert its orthopedic footfall into a broader healthcare ecosystem. The challenge, however, will be talent acquisition. The company recently acknowledged the loss of some key medical personnel due to past management friction, making the recruitment of the "experienced team of oncologists" mentioned in today’s announcement critical to the department’s success.
Beyond Ahmedabad, Shalby is eyeing a broader national footprint with planned expansions in Lucknow, Kolkata, Nagpur, and Pune over the next two to five years. Each of these new facilities is expected to feature 200 to 250 beds, with oncology likely baked into the core service offering from day one. This aggressive scaling suggests that Shalby is no longer content being a regional leader in a niche field. Instead, it is positioning itself as a diversified healthcare conglomerate capable of challenging the national incumbents on every front, from the operating theater to the radiation bunker.
Explore more exclusive insights at nextfin.ai.
